OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Bimekizumab versus Adalimumab in Plaque Psoriasis
Richard B. Warren, Andrew Blauvelt, Jerry Bagel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 130-141
Open Access | Times Cited: 168
Richard B. Warren, Andrew Blauvelt, Jerry Bagel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 130-141
Open Access | Times Cited: 168
Showing 1-25 of 168 citing articles:
IL-17 and IL-17-producing cells in protection versus pathology
Kingston H. G. Mills
Nature reviews. Immunology (2022) Vol. 23, Iss. 1, pp. 38-54
Open Access | Times Cited: 553
Kingston H. G. Mills
Nature reviews. Immunology (2022) Vol. 23, Iss. 1, pp. 38-54
Open Access | Times Cited: 553
Antibodies to watch in 2022
Hélène Kaplon, Alicia M. Chenoweth, Silvia Crescioli, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 303
Hélène Kaplon, Alicia M. Chenoweth, Silvia Crescioli, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 303
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B. Warren, Mark Lebwohl, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 142-152
Open Access | Times Cited: 279
Kristian Reich, Richard B. Warren, Mark Lebwohl, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 142-152
Open Access | Times Cited: 279
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Sophie Glatt, Gregor B. E. Jemec, Seth Forman, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 11, pp. 1279-1279
Open Access | Times Cited: 130
Sophie Glatt, Gregor B. E. Jemec, Seth Forman, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 11, pp. 1279-1279
Open Access | Times Cited: 130
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 110
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 110
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Iain B. McInnes, Akihiko Asahina, Laura C. Coates, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 25-37
Open Access | Times Cited: 101
Iain B. McInnes, Akihiko Asahina, Laura C. Coates, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 25-37
Open Access | Times Cited: 101
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 4, pp. 515-526
Open Access | Times Cited: 70
Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 4, pp. 515-526
Open Access | Times Cited: 70
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 43
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 43
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
The Role of IL-17 Cytokines in Psoriasis
Megan Mosca, Julie Hong, Edward Hadeler, et al.
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 409-418
Open Access | Times Cited: 61
Megan Mosca, Julie Hong, Edward Hadeler, et al.
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 409-418
Open Access | Times Cited: 61
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 7, pp. 735-735
Open Access | Times Cited: 42
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 7, pp. 735-735
Open Access | Times Cited: 42
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 8, pp. 1777-1792
Open Access | Times Cited: 41
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 8, pp. 1777-1792
Open Access | Times Cited: 41
Targeting lymphoid-derived IL-17 signaling to delay skin aging
Paloma Solá, Elisabetta Mereu, Júlia Bonjoch, et al.
Nature Aging (2023) Vol. 3, Iss. 6, pp. 688-704
Open Access | Times Cited: 40
Paloma Solá, Elisabetta Mereu, Júlia Bonjoch, et al.
Nature Aging (2023) Vol. 3, Iss. 6, pp. 688-704
Open Access | Times Cited: 40
Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features
Giovanni Monteleone, A. Moscardelli, Alice Colella, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 10, pp. 103410-103410
Open Access | Times Cited: 34
Giovanni Monteleone, A. Moscardelli, Alice Colella, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 10, pp. 103410-103410
Open Access | Times Cited: 34
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1404-1414
Open Access | Times Cited: 28
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1404-1414
Open Access | Times Cited: 28
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 6, pp. 749-759
Open Access | Times Cited: 27
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 6, pp. 749-759
Open Access | Times Cited: 27
Advances in psoriasis research: From pathogenesis to therapeutics
Dineshwar Sugumaran, Audrey Chee Hui Yong, Johnson Stanslas
Life Sciences (2024) Vol. 355, pp. 122991-122991
Closed Access | Times Cited: 15
Dineshwar Sugumaran, Audrey Chee Hui Yong, Johnson Stanslas
Life Sciences (2024) Vol. 355, pp. 122991-122991
Closed Access | Times Cited: 15
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Yi Song, Jian Li, Yuzhang Wu
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Yi Song, Jian Li, Yuzhang Wu
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Biologics (2021) Vol. Volume 15, pp. 247-253
Open Access | Times Cited: 48
Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Biologics (2021) Vol. Volume 15, pp. 247-253
Open Access | Times Cited: 48
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*
Ruth Oliver, James G. Krueger, Sophie Glatt, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 4, pp. 652-663
Open Access | Times Cited: 42
Ruth Oliver, James G. Krueger, Sophie Glatt, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 4, pp. 652-663
Open Access | Times Cited: 42
